Marina M. Olaneta-Lopez
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Cardiomyocyte-Specific Inhibition of p53 Signaling as a Therapeutic Strategy for Arrhythmogenic Right Ventricular Cardiomyopathy Type 5.
Journal: Circulation research
Published: August 04, 2026
CRISPR activation to repair electrocardiogram abnormalities caused by a FLNC truncating variant in mice.
Journal: European heart journal
Published: July 09, 2025
Unraveling Comorbidities Contribution to Cardiac Diastolic Dysfunction and Heart Failure.
Journal: Circulation. Heart failure
Published: November 29, 2024
Presence of fetal microchimerisms in the heart and effect on cardiac repair.
Journal: Frontiers in cell and developmental biology
Published: February 23, 2024
Author Correction: Assessment of myocardial viscoelasticity with Brillouin spectroscopy in myocardial infarction and aortic stenosis models.
Journal: Scientific reports
Published: December 24, 2021
Early Preventive Treatment With Enalapril Improves Cardiac Function and Delays Mortality in Mice With Arrhythmogenic Right Ventricular Cardiomyopathy Type 5.
Journal: Circulation. Heart failure
Published: August 20, 2021
The SRSF4-GAS5-Glucocorticoid Receptor Axis Regulates Ventricular Hypertrophy.
Journal: Circulation research
Published: August 02, 2021
Functional Impact and Regulation of Alternative Splicing in Mouse Heart Development and Disease.
Journal: Journal of cardiovascular translational research
Published: June 28, 2021
Severe Cardiac Dysfunction and Death Caused by Arrhythmogenic Right Ventricular Cardiomyopathy Type 5 Are Improved by Inhibition of Glycogen Synthase Kinase-3β.
Journal: Circulation
Published: October 01, 2019
Last Updated: 09/26/2026